Cargando…
Prostate cancer cells synergistically defend against CD8 (+) T cells by secreting exosomal PD‐L1
BACKGROUND: Metastatic castration‐resistant prostate cancer (mCRPC) remains fatal and incurable, despite a variety of treatments that can delay disease progression and prolong life. Immune checkpoint therapy is a promising treatment. However, emerging evidence suggests that exosomal programmed necro...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469662/ https://www.ncbi.nlm.nih.gov/pubmed/37501397 http://dx.doi.org/10.1002/cam4.6275 |